News
UK MHRA approves Accord Healthcare’s anti-PD-1 monoclonal antibody, serplulimab to treat aggressive form of SCLC: United Kingdom Monday, June 23, 2025, 09:00 Hrs [IST] The Medic ...
Shardul Nautiyal, Mumbai Monday, June 23, 2025, 08:00 Hrs [IST] ...
Telangana IDMA eyes growth strategies of Gujarat & Maharashtra to replicate in local pharma sector: Peethaambaran Kunnathoor, Chennai. Monday, June 23, 2025, 08:00 Hrs [IST] Altho ...
Even though the Central government had revised the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) for the pharma industry last year, it remains toothless and statutorily unbinding, ...
The JSS Academy of Higher Education & Research (JSSAHER) vice chancellor Dr H Basavanagowdappa has pointed out that Indian pharma industry should now think of GMP as the hygiene code for manufacturing ...
FDI inflow into hospitals & diagnostic centres grew 4 per cent in FY25: Gireesh Babu, New Delhi Monday, June 23, 2025, 08:00 Hrs [IST] The Foreign Direct Investment (FDI) equity i ...
PCI asks institutions to submit appeal regarding statutory documents for AY25-26: Gireesh Babu, New Delhi Saturday, June 21, ...
CereVasc receives Health Canada investigational testing authorization to conduct STRIDE trial to evaluate eShunt System: Boston Saturday, June 21, 2025, 14:00 Hrs [IST] CereVasc I ...
Refeyn announces USP recognizes mass photometry in new AAV reference standards for gene therapy quality: Oxford, UK Friday, ...
KARL STORZ US gets expanded indication for Solo+ Tympanostomy tube device to use in pediatric patients aged 6 to 24 months old: El Segundo, California Saturday, June 21, 2025, 17: ...
Moleculin Biotech gets US FDA positive feedback on paediatric study plan for Annamycin in children with R/R AML: Houston Saturday, June 21, 2025, 15:00 Hrs [IST] Moleculin Biotech ...
GRAIL announces positive top-line results from Galleri PATHFINDER 2 study: Menlo Park, California Saturday, June 21, 2025, 18:00 Hrs [IST] GRAIL, Inc, a healthcare company whose m ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results